|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9305
|
|
pubmed:dateCreated |
2002-2-20
|
|
pubmed:abstractText |
BCR-ABL, a constitutively activated tyrosine kinase, is the oncogene that causes Philadelphia-chromosome-positive (Ph+) leukaemia. STI571, a competitive inhibitor at the ATP-binding site of BCR-ABL, has been shown to have high activity in this type of leukaemia. However, most patients with advanced disease relapse despite continued treatment with STI571. We aimed to find out whether point mutations in BCR-ABL cause resistance to STI571.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
9
|
|
pubmed:volume |
359
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
487-91
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11853795-Drug Resistance, Neoplasm,
pubmed-meshheading:11853795-Fusion Proteins, bcr-abl,
pubmed-meshheading:11853795-Humans,
pubmed-meshheading:11853795-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:11853795-Piperazines,
pubmed-meshheading:11853795-Point Mutation,
pubmed-meshheading:11853795-Prospective Studies,
pubmed-meshheading:11853795-Protein-Tyrosine Kinases,
pubmed-meshheading:11853795-Pyrimidines,
pubmed-meshheading:11853795-Sequence Analysis, DNA
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.
|
|
pubmed:affiliation |
Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, Ismaningerstrasse 22, 81675, Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
